ECCO 2018: Novel treatments in IBD
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.
Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.
ESCP 2017 delegates give their highlights, plus a report on the ESCP/ECCO symposium on ulcerative colitis and a focus on quality of life for patients with perianal Crohn’s disease.
By Maria Dalby (article) and Peter Mas Mollinedo (interviews) The decision to perform a colectomy in patients with ulcerative colitis (UC) should not be made lightly. Such a… read more.
Author: Bruce Sylvester Exenatide, a drug used to treat diabetes, could have disease-modifying potential in the treatment of Parkinson’s disease, researchers reported on August 3, 2017 in The… read more.
Professor Peter Johnson (Southampton, UK) tells us what’s new with response-adapted therapy and what are the benefits to patients.
Author: Gary Finnegan A ‘brain training’ game developed by researchers at the University of Cambridge, UK, could help improve the memory of patients in the very earliest stages… read more.
Adding antibiotic treatment to standard drainage of simple skin abscesses appears to improve healing, researchers reported on June 29, 2017 in the NEJM/New England Journal of Medicine.
An entertaining case discussion session, chaired by Craig Moskowitz at ICML-14, highlighted some of the hot debates in Hodgkin lymphoma as discussed here by Professor Stephen Ansell (Rochester, USA),… read more.
Interviewer: Esther Drain Dr Toby Eyre (Oxford), Professor Anas Younes (MSKCC, USA), Dr Andrew Davies (Southampton) and Dr Graham Collins (Oxford) discuss new data in CAR T cell therapy and the first EZH2 inhibitor, tazemetostat, in… read more.
By Maria Dalby (article) and Esther Drain (interviews) Even in an era of rapid progress in terms of new agents and treatment approaches, stem cell transplantation (SCT) continues… read more.